Kavita Sharma, MD
Cardiovascular Disease · Delaware, OHNPI 1013192343
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $61,503 of the $84,610 with a category attached, or 72.7%. Amgen accounts for 85.7% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $41,958 and has fallen 99.7% since, to $130 in 2025. Among cardiovascular disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 145 payments — averaging $583.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$73K
- Regeneron$9K
- Novartis$2K
- AstraZeneca$216
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$188
- Novo Nordisk$160
- plus $579 from 10 others
Across 4 payments — averaging $23,482 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$94K
What the payments were for
- Consulting fees$15,45018%
- Speaking & faculty fees$61,50373%
- Travel & lodging$3,8775%
- Food & beverage$3,7814%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 83 | $72,547 |
| Regeneron | 12 | $8,621 |
| Novartis | 9 | $2,299 |
| AstraZeneca | 8 | $216 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $188 |
| Novo Nordisk | 9 | $160 |
| Medtronic | 2 | $138 |
| Abbott | 1 | $109 |
| Boston Scientific | 2 | $108 |
| E.r. Squibb & Sons, L.L.C. | 4 | $79 |
| Sanofi-aventis U.S. LLC | 2 | $41 |
| Boehringer Ingelheim | 2 | $35 |
| ZOLL Circulation Inc | 1 | $22 |
| Johnson & Johnson | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$84,610 in reported general payments places this provider in the 95th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 305 | $332,550 |
| Repatha SureclickEvolocumab | 357 | $290,077 |
| EntrestoSacubitril/Valsartan | 71 | $69,667 |
| Praluent PenAlirocumab | 72 | $63,633 |
| XareltoRivaroxaban | 55 | $56,349 |
| NexlizetBempedoic Acid/Ezetimibe | 40 | $19,576 |
| JardianceEmpagliflozin | 15 | $19,197 |
| Icosapent Ethyl | 36 | $12,369 |
| NexletolBempedoic Acid | 32 | $12,180 |
| VascepaIcosapent Ethyl | 21 | $10,162 |
| BrilintaTicagrelor | 11 | $9,133 |
| Ezetimibe | 289 | $6,035 |
| Metoprolol Succinate | 422 | $5,038 |
| Ranolazine ErRanolazine | 36 | $3,481 |
| Atorvastatin Calcium | 390 | $2,876 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $2,299 | $69,66771 claims |
| Johnson & JohnsonXarelto | $18 | $56,34955 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $17 | $31,75772 claims |
| Boehringer IngelheimJardiance | $35 | $19,19715 claims |
| AstraZenecaBrilinta | $216 | $9,13311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 827 cardiovascular disease providers in Ohio.
Other cardiovascular disease in Delaware
- Guilherme AttizzaniCleveland$1.3M
- Gregory LamCircleville$428K
- Emil HayekHudson$379K
- Abraham LincoffCleveland$369K
- Oussama WazniCleveland$367K
- Ian NeelandCleveland$329K
- Kamal ShemisaCincinnati$314K
- Mehdi ShishehborElyria$237K
- Abdu HawwaGarfield Hts$234K
- Jayanta MukherjeeColumbus$227K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.